Enhanced calcium release in the acute neuronopathic form of Gaucher disease

被引:111
作者
Pelled, D
Trajkovic-Bodennec, S
Lloyd-Evans, E
Sidransky, E
Schiffmann, R
Futerman, AH
机构
[1] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel
[2] NIMH, Clin Neurosci Branch, Bethesda, MD 20892 USA
[3] NHGRI, Med Genet Branch, NIH, Bethesda, MD 20892 USA
[4] NINDS, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA
关键词
Gaucher disease; lysosomal storage disease; glucocerebrosidase; glucosylceramide; glucosylphingosine; calcium; neuronopathic;
D O I
10.1016/j.nbd.2004.09.004
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Gaucher disease is an inherited metabolic disorder caused by defective activity of the lysosomal enzyme, glucocerebrosidase, resulting in accumulation of the lipids, glucosylceramide (GlcCer), and glucosylsphingosine (GlcSph). Little is known about the mechanism leading from lipid accumulation to disease, particularly in the acute and subacute neuronopathic forms of Gaucher disease, types 2 and 3, respectively. Recent work from our laboratory has shown, in animal models, that GlcCer enhances agonist-induced calcium release from intracellular stores via the ryanodine receptor, which results in neuronal cell death. We now test whether calcium release is altered in human brain tissue obtained post-mortem from Gaucher disease patients. Agonist-induced calcium release via the ryanodine receptor was significantly enhanced (P < 0.05) in brain microsomes from the acute neuronopathic form of Gaucher disease (type 2) (43 +/- 6% of the calcium in microsomes) compared to the subacute (type 3) (27 +/- 3%) and the non-neuronopathic (type 1) (28 +/- 6%) forms, and controls (18 +/- 3%), and correlated with levels of GlcCer accumulation. These findings suggest that defective calcium homeostasis may be a mechanism responsible for neuropathophysiology in acute neuronopathic Gaucher disease, and may potentially offer new therapeutic approaches for disease management. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:83 / 88
页数:6
相关论文
共 26 条
[1]  
ADACHI M, 1967, ARCH PATHOL, V83, P513
[2]   Calcium - a life and death signal [J].
Berridge, MJ ;
Bootman, MD ;
Lipp, P .
NATURE, 1998, 395 (6703) :645-648
[3]  
Beutler E., 2001, METABOLIC MOL BASES, V3, P3635
[4]   Simultaneous quantification of lyso-neutral glycosphingolipids and neutral glycosphingolipids by N-acetylation with [3H]acetic anhydride [J].
Bodennec, J ;
Trajkovic-Bodennec, S ;
Futerman, AH .
JOURNAL OF LIPID RESEARCH, 2003, 44 (07) :1413-1419
[5]   Aminopropyl solid phase extraction and 2 D TLC of neutral glycosphingolipids and neutral lysoglycosphingolipids [J].
Bodennec, J ;
Pelled, D ;
Futerman, AH .
JOURNAL OF LIPID RESEARCH, 2003, 44 (01) :218-226
[6]  
BORGES JS, 1995, EUR J OPHTHALMOL, V5, P69
[7]   Palmitoyl-CoA potentiates the Ca2+ release elicited by cyclic ADP-ribose [J].
Chini, EN ;
Dousa, TP .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 1996, 270 (02) :C530-C537
[8]   Neuronopathic forms of Gaucher's disease [J].
Erikson, A ;
Bembi, B ;
Schiffmann, R .
BAILLIERES CLINICAL HAEMATOLOGY, 1997, 10 (04) :711-723
[9]   Mutation analysis of the acid β-glucosidase gene in a patient with type 3 Gaucher disease and neutralizing antibody to alglucerase [J].
Germain, DP ;
Kaneski, CR ;
Brady, RO .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2001, 483 (1-2) :89-94
[10]   Phenotypic continuum in neuronopathic Gaucher disease: An intermediate phenotype between type 2 and type 3 [J].
Goker-Alpan, O ;
Schiffmann, R ;
Park, JK ;
Stubblefield, BK ;
Tayebi, N ;
Sidransky, E .
JOURNAL OF PEDIATRICS, 2003, 143 (02) :273-276